For advanced METex14 skipping‐mutated NSCLC, a real‐world study suggested that first‐line MET inhibitor had greater efficacy than immunomonotherapy or chemoimmunotherapy.15 This evidence concerns the gene MET and non-small cell lung carcinoma.